Allogeneic hematopoietic stem cell transplantation (HSCT) was the first cellular immunotherapy to arise and, due to its overwhelming success, it remains a mainstay in the treatment of refractory leukemias and lymphomas [1]. More than 16,000 allogeneic transplantations per year are performed in Europe alone, most of them for refractory myeloid and lymphoid neoplasias [1]. Even though the primary goal of HSCT was “organ replacement” of a diseased by a healthy hematopoietic system, its pioneers very early on recognized the ability of the graft to eradicate residual blasts [2‒5]. The antileukemic activity, however, came at a price: at the time termed “secondary disease,” now known as graft-versus-host disease (GvHD), which the first generation of transplanters surmised were both immune-mediated reactions of grafted cells with host, and which they equally surmised were birds of a feather [3, 6]. Both hypotheses turned out to be true [7‒9]. To this day, despite a greater armamentarium of immunosuppressive medications and a better understanding of histocompatibility, HSCT remains a walk on the edge between GvHD from too much and relapse from too little activity of the grafted T cells [10].

From this conflict, the first more exclusive cellular immunotherapy, donor lymphocyte infusion, arose, which harbors the same risk of GvHD as unmodified stem cell grafts, but was, with carefully escalating dosing, shown to be exquisitely effective in chronic myeloid leukemia [11, 12], the most prevalent indication for allogeneic transplantation before the advent of the BCR-ABL kinase inhibitors [13]. The risk of GvHD development from allogeneic lymphocyte transfer has fueled, and continues to fuel, the quest for ever more specific cellular immunotherapies, either by selecting desired T-cell specificities from allogeneic T-cell products, educating T cells to lose alloreactivity, depleting alloreactive T cells to enrich memory cells, or by endowing autologous T cells with the ability to specifically recognize desired antigens, predominantly by transfer of artificial genes encoding specific chimeric antigen receptors (CARs) or T-cell receptors [14‒31].

This collection of articles authored by experts in the field of cellular immunotherapy provides examples of such highly innovative and promising therapies. The articles deal with innovative cell therapies that are already regularly used in the clinics; others provide glimpses into the near future, identifying areas of unmet medical need and possible avenues toward their resolution. As any such article collection must be, it is far from complete in representing the full breadth of available and potential future cellular immunotherapies, nor weighted in terms of the respective magnitude of the individual therapy’s roles in current clinical practice. Suffice it to say, cellular immunotherapy, both with primary and genetically modified T cells, is here, with only more to come. Or is it?

If the editors of Transfusion Medicine and Hemotherapy were not fascinated by the emerging field of cellular immunotherapy and wanted to share their fascination with the readership, this special collection of articles would not have been proposed. And yet this article collection comes with a black box warning: The production of cell therapeutics is (i) almost always customized and personalized, (ii) more hand-crafted than factory-produced, and (iii) inherently more expensive by several orders of magnitude than any other form of therapy developed to date, including in vivo gene therapeutics.

The systemic application and potentially life-long persistence of genetically modified cells require careful quality control of each individual product, using assays that not just quantify the active substance but also allow predictions about its fate in vivo. Cell therapy manufacturing and testing essentially follows the same regulatory framework as the manufacturing of conventional drugs, whether they are small molecules or biologicals, except that in most cases each dose constitutes a batch of the highly personalized cellular medicinal product, hugely inflating the quality control effort per individual dose.

The financial toxicity of cellular immunotherapies is undeniable, and “cell engineers” are aware of all these challenges. The currently centrally approved cellular immunotherapies cost between 200,000 and 400,000 euros. Trials are ongoing that seek to extend approved cellular therapies to currently not eligible patient groups (e.g., CD19-CAR-T cells for elderly patients), and to diseases that are orders of magnitude more common (e.g., CD19-CAR-T cells for autoimmune disease) [32‒34]. Unfortunately, some approved cellular immunotherapies no longer promise the coveted cures, but at best only moderately long remissions or a bridge to transplantation [31, 35, 36] and infectious complications after CAR-T-cell therapy are frequent [37]. Recently, the Federal Joint Committee (Gemeinsamer Bundesausschuss [G-BA]) withdrew the temporary coverage for a CAR-T-cell immunotherapy for multiple myeloma, namely, Abecma (www.g-ba.de/bewertungsverfahren/nutzenbewertung/1068/#nutzenbewertung). Negotiations on reimbursement for cellular immunotherapies sometimes fail because price expectations of the pharmaceutical manufacturers and evaluation of the therapy by health technology experts appear to be irreconcilable.

Nevertheless, cellular therapies are at the forefront of research and the development of new therapeutic approaches is in full swing. The use of unmanipulated [15, 16, 38‒41] and genetically modified T cells [26‒31], natural killer [42‒44], and cytokine-induced killer cells [45] has been shown to be effective against infections and various cancers. In order to make allogeneic cells more suitable and obtain maximally standardized products, lymphocytes are increasingly being generated from in vitro induced pluripotent stem cells or enriched from umbilical cord blood and off-the-shelf therapies are under development [46‒51]. However, challenges remain to be addressed, as phenotype and effector functions of the in vitro generated cells are distinct from those of peripheral blood-derived primary cells currently used in the clinic. CAR-T-cell therapy has achieved outstanding clinical success in hematology with CD19-specific CAR-T cells against B-cell leukemias and lymphomas and B-cell maturation antigen-specific CAR-T cells for the treatment of multiple myeloma, significantly improving patient survival [31, 37]. Due to other challenges, clinical experience with CAR-T therapy in oncology remains limited. These challenges include limited efficacy, antigen escape, low persistence of effector cells, poor enrichment and tumor infiltration, the immunosuppressive microenvironment, and the risk of secondary malignancies. These aspects must be considered disease- and context-specific when developing these therapies.

Additionally, a lot of work is also being done on optimizing the binding between receptors and target. Indirect CAR technologies including universal adapter CARs and “on-off” switchable CARs may be the future of CAR therapies [52‒56]. These CARs expand recognition beyond the well-known targets CD19 and B-cell maturation antigen and may provide a simple solution to the complex challenge of antigen heterogeneity, especially in the treatment of solid tumors. Recently, it was also shown that regulating the single chain variable fragment affinity directly regulates CAR-T-cell activity [57]. Therefore, switching modules, which usually function under physiological conditions, can increase the affinity and also the specificity of cellular products. The affinity changes are reversible and the switching can be repeatedly induced.

“Cell Engineers” are aware of these challenges, and there are increasing efforts to produce cellular drugs at specialized academic institutions by creating new and improving available technologies, thus counteracting de-commercialization [58, 59]. Tools that make the generation of genetically modified effector cells cost-efficient, highly reproducible, and scalable will revolutionize cellular therapies for severely affected patients and will thereby open up new areas. New flexible concepts will be required in the era of patient-specific therapies to make the dream of accessibility for a large patient collective in a reasonable time frame come true.

H.B. acknowledges research support from Bayer, Chugai, EryDel, Miltenyi Biotech, Polyphor, Sandoz-Hexal (a Novartis company), Stage (a Celgene company), Terumo BCT, and uniQure; honoraria and speakers’ fees from Chugai, Fresenius, Genzyme, Kiadis, medac, Miltenyi Biotec, Novartis, Sandoz-Hexal, and Terumo BCT; consultancy and membership in advisory boards for Boehringer Ingelheim Vetmedica, Celgene (a BMS company), Genzyme, medac, Novartis, Sandoz-Hexal, Stage, and Terumo BCT; royalties from medac; and stock ownership from Healthineers. B.E.-V. acknowledges research support from Miltenyi Biotech and Glycotope.

Not applicable.

H.B. and B.E.-V. conceived, wrote, and edited the manuscript.

1.
Kean
LS
,
Blazar
BR
.
Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation
.
J Clin Invest
.
2024
;
134
(
8
):
e179944
.
2.
Mathe
G
.
Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis
.
Biomed Pharmacother
.
1989
;
43
(
8
):
551
61
.
3.
Mathe
G
,
Schwarzenberg
L
,
Amiel
JL
,
Cattan
A
,
Schneider
M
,
Lapeyraque
F
.
[Bone marrow transplantation in the treatment of leukemia]
.
Presse Med
.
1965
;
73
:
1043
6
.
4.
Buckner
CD
,
Epstein
RB
,
Rudolph
RH
,
Clift
RA
,
Storb
R
,
Thomas
ED
.
Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia
.
Blood
.
1970
;
35
(
6
):
741
50
.
5.
Thomas
ED
,
Lochte
HL
Jr
,
Cannon
JH
,
Sahler
OD
,
Ferrebee
JW
.
Supralethal whole body irradiation and isologous marrow transplantation in man
.
J Clin Invest
.
1959
;
38
(
10 Pt 1–2
):
1709
16
.
6.
Storb
R
,
Rudolph
RH
,
Thomas
ED
.
Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture
.
J Clin Invest
.
1971
;
50
(
6
):
1272
5
.
7.
Dholaria
B
,
Savani
BN
,
Hamilton
BK
,
Oran
B
,
Liu
HD
,
Tallman
MS
, et al
.
Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American society of transplantation and cellular therapy
.
Transpl Cel Ther
.
2021
;
27
(
1
):
6
20
.
8.
Dholaria
B
,
Savani
BN
,
Labopin
M
,
Luznik
L
,
Ruggeri
A
,
Mielke
S
, et al
.
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
.
Haematologica
.
2020
;
105
(
1
):
47
58
.
9.
Dholaria
B
,
Labopin
M
,
Angelucci
E
,
Ciceri
F
,
Diez-Martin
JL
,
Bruno
B
, et al
.
Impact of total body irradiation-vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia
.
Am J Hematol
.
2020
;
95
(
10
):
1200
8
.
10.
Michniacki
TF
,
Choi
SW
,
Peltier
DC
.
Immune suppression in allogeneic hematopoietic stem cell transplantation
.
Handb Exp Pharmacol
.
2022
;
272
:
209
43
.
11.
Bleakley
M
,
Heimfeld
S
,
Loeb
KR
,
Jones
LA
,
Chaney
C
,
Seropian
S
, et al
.
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts
.
J Clin Invest
.
2015
;
125
(
7
):
2677
89
.
12.
Kolb
HJ
,
Mittermüller
J
,
Clemm
C
,
Holler
E
,
Ledderose
G
,
Brehm
G
, et al
.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
.
Blood
.
1990
;
76
(
12
):
2462
5
.
13.
Schiffer
CA
.
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
.
N Engl J Med
.
2007
;
357
(
3
):
258
65
.
14.
Roy
DC
,
Walker
I
,
Maertens
J
,
Lewalle
P
,
Olavarria
E
,
Selleslag
D
, et al
.
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
.
Leukemia
.
2020
;
34
(
7
):
1907
23
.
15.
Mohn
N
,
Grote-Levi
L
,
Wattjes
MP
,
Bonifacius
A
,
Holzwart
D
,
Hopfner
F
, et al
.
Directly isolated allogeneic virus-specific T cells in progressive multifocal leukoencephalopathy
.
JAMA Neurol
.
2024
;
81
(
11
):
1187
98
.
16.
Bonifacius
A
,
Lamottke
B
,
Tischer-Zimmermann
S
,
Schultze-Florey
R
,
Goudeva
L
,
Heuft
HG
, et al
.
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
.
J Clin Invest
.
2023
;
133
(
12
):
e163548
.
17.
Tischer
S
,
Priesner
C
,
Heuft
HG
,
Goudeva
L
,
Mende
W
,
Barthold
M
, et al
.
Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells
.
J Transl Med
.
2014
;
12
:
336
.
18.
Gasior Kabat
M
,
Bueno
D
,
Sisinni
L
,
De Paz
R
,
Mozo
Y
,
Perona
R
, et al
.
Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases
.
Int J Hematol
.
2021
;
114
(
1
):
116
23
.
19.
Tzannou
I
,
Papadopoulou
A
,
Naik
S
,
Leung
K
,
Martinez
CA
,
Ramos
CA
, et al
.
Off-the-Shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation
.
J Clin Oncol
.
2017
;
35
(
31
):
3547
57
.
20.
Dadwal
SS
,
Bansal
R
,
Schuster
MW
,
Yared
JA
,
Myers
GD
,
Matzko
M
, et al
.
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
.
Blood Adv
.
2024
;
8
(
17
):
4740
50
.
21.
Mangare
C
,
Tischer-Zimmermann
S
,
Bonifacius
A
,
Riese
SB
,
Dragon
AC
,
Blasczyk
R
, et al
.
Variances in antiviral memory T-cell repertoire of CD45RA- and cd62l-depleted lymphocyte products reflect the need of individual T-cell selection strategies to reduce the risk of GvHD while preserving antiviral immunity in adoptive T-cell therapy
.
Transfus Med Hemother
.
2022
;
49
(
1
):
30
43
.
22.
Bleakley
M
,
Sehgal
A
,
Seropian
S
,
Biernacki
MA
,
Krakow
EF
,
Dahlberg
A
, et al
.
Naive T-cell depletion to prevent chronic graft-versus-host disease
.
J Clin Oncol
.
2022
;
40
(
11
):
1174
85
.
23.
Muller
N
,
Landwehr
K
,
Langeveld
K
,
Stenzel
J
,
Pouwels
W
,
van der Hoorn
MAWG
, et al
.
Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells
.
Cytotherapy
.
2018
;
20
(
4
):
532
42
.
24.
Merker
M
,
Salzmann-Manrique
E
,
Katzki
V
,
Huenecke
S
,
Bremm
M
,
Bakhtiar
S
, et al
.
Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions
.
Biol Blood Marrow Transpl
.
2019
;
25
(
7
):
1281
92
.
25.
Bleakley
M
,
Heimfeld
S
,
Jones
LA
,
Turtle
C
,
Krause
D
,
Riddell
SR
, et al
.
Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells
.
Biol Blood Marrow Transpl
.
2014
;
20
(
5
):
705
16
.
26.
Baker
DJ
,
Arany
Z
,
Baur
JA
,
Epstein
JA
,
June
CH
.
CAR T therapy beyond cancer: the evolution of a living drug
.
Nature
.
2023
;
619
(
7971
):
707
15
.
27.
Golikova
EA
,
Alshevskaya
AA
,
Alrhmoun
S
,
Sivitskaya
NA
,
Sennikov
SV
.
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges
.
J Transl Med
.
2024
;
22
(
1
):
897
.
28.
Miliotou
AN
,
Papadopoulou
LC
.
CAR T-cell therapy: a new era in cancer immunotherapy
.
Curr Pharm Biotechnol
.
2018
;
19
(
1
):
5
18
.
29.
Sterner
RC
,
Sterner
RM
.
CAR-T cell therapy: current limitations and potential strategies
.
Blood Cancer J
.
2021
;
11
(
4
):
69
.
30.
Larson
RC
,
Maus
MV
.
Recent advances and discoveries in the mechanisms and functions of CAR T cells
.
Nat Rev Cancer
.
2021
;
21
(
3
):
145
61
.
31.
Cappell
KM
,
Kochenderfer
JN
.
Long-term outcomes following CAR T cell therapy: what we know so far
.
Nat Rev Clin Oncol
.
2023
;
20
(
6
):
359
71
.
32.
Marofi
F
,
Rahman
HS
,
Achmad
MH
,
Sergeevna
KN
,
Suksatan
W
,
Abdelbasset
WK
, et al
.
A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions
.
Front Immunol
.
2021
;
12
:
681984
.
33.
Bailen
R
,
Iacoboni
G
,
Delgado
J
,
López-Corral
L
,
Hernani-Morales
R
,
Ortiz-Maldonado
V
, et al
.
Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO
.
Transpl Cel Ther
.
2024
;
30
(
10
):
988 e1
1
.
34.
Mackensen
A
,
Müller
F
,
Mougiakakos
D
,
Böltz
S
,
Wilhelm
A
,
Aigner
M
, et al
.
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
.
Nat Med
.
2022
;
28
(
10
):
2124
32
.
35.
Mougiakakos
D
,
Sengupta
R
,
Gold
R
,
Schroers
R
,
Haghikia
A
,
Lorente
M
, et al
.
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders
.
Cytotherapy
.
2024
.
36.
Schett
G
,
Mackensen
A
,
Mougiakakos
D
.
CAR T-cell therapy in autoimmune diseases
.
Lancet
.
2023
;
402
(
10416
):
2034
44
.
37.
Cordas Dos Santos
DM
,
Tix
T
,
Shouval
R
,
Gafter-Gvili
A
,
Alberge
JB
,
Cliff
ERS
, et al
.
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
.
Nat Med
.
2024
;
30
(
9
):
2667
78
.
38.
Pfeiffer
T
,
Tzannou
I
,
Wu
M
,
Ramos
C
,
Sasa
G
,
Martinez
C
, et al
.
Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting
.
Clin Cancer Res
.
2023
;
29
(
2
):
324
30
.
39.
Keller
MD
,
Hanley
PJ
,
Chi
YY
,
Aguayo-Hiraldo
P
,
Dvorak
CC
,
Verneris
MR
, et al
.
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
.
Nat Commun
.
2024
;
15
(
1
):
3258
.
40.
Mahadeo
KM
,
Baiocchi
R
,
Beitinjaneh
A
,
Chaganti
S
,
Choquet
S
,
Dierickx
D
, et al
.
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
.
Lancet Oncol
.
2024
;
25
(
3
):
376
87
.
41.
Neller
MA
,
Ambalathingal
GR
,
Hamad
N
,
Sasadeusz
J
,
Pearson
R
,
Holmes-Liew
CL
, et al
.
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
.
Nat Commun
.
2024
;
15
(
1
):
10339
.
42.
Bexte
T
,
Botezatu
L
,
Miskey
C
,
Gierschek
F
,
Moter
A
,
Wendel
P
, et al
.
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
.
Mol Ther
.
2024
;
32
(
7
):
2357
72
.
43.
Liu
E
,
Marin
D
,
Banerjee
P
,
Macapinlac
HA
,
Thompson
P
,
Basar
R
, et al
.
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
.
N Engl J Med
.
2020
;
382
(
6
):
545
53
.
44.
Marofi
F
,
Saleh
MM
,
Rahman
HS
,
Suksatan
W
,
Al-Gazally
ME
,
Abdelbasset
WK
, et al
.
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
.
Stem Cel Res Ther
.
2021
;
12
(
1
):
374
.
45.
Biondi
M
,
Tettamanti
S
,
Galimberti
S
,
Cerina
B
,
Tomasoni
C
,
Piazza
R
, et al
.
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden
.
Blood
.
2023
;
141
(
21
):
2587
98
.
46.
Baker
DJ
,
June
CH
.
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases
.
Cell
.
2024
;
187
(
18
):
4826
8
.
47.
Castelli
S
,
Young
RM
,
June
CH
.
Off-the-shelf CAR T cells to treat cancer
.
Cell Res
.
2022
;
32
(
12
):
1036
7
.
48.
Georgiadis
C
,
Nickolay
L
,
Syed
F
,
Zhan
H
,
Gkazi
SA
,
Etuk
A
, et al
.
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in “off the shelf” chimeric antigen receptor T-cell therapies to widen transplant options
.
Haematologica
.
2024
;
109
(
12
):
3941
51
.
49.
Netsrithong
R
,
Garcia-Perez
L
,
Themeli
M
.
Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
.
Front Immunol
.
2023
;
14
:
1325209
.
50.
van der Stegen
SJC
,
Lindenbergh
PL
,
Petrovic
RM
,
Xie
H
,
Diop
MP
,
Alexeeva
V
, et al
.
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells
.
Nat Biomed Eng
.
2022
;
6
(
11
):
1284
97
.
51.
Chen
S
,
van den Brink
MRM
.
Allogeneic “Off-the-Shelf” CAR T cells: challenges and advances
.
Best Pract Res Clin Haematol
.
2024
;
37
(
3
):
101566
.
52.
Schlegel
LS
,
Werbrouck
C
,
Boettcher
M
,
Schlegel
P
.
Universal CAR 2.0 to overcome current limitations in CAR therapy
.
Front Immunol
.
2024
;
15
:
1383894
.
53.
Atar
D
,
Ruoff
L
,
Mast
AS
,
Krost
S
,
Moustafa-Oglou
M
,
Scheuermann
S
, et al
.
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia
.
Leukemia
.
2024
;
38
(
10
):
2183
95
.
54.
Nixdorf
D
,
Sponheimer
M
,
Berghammer
D
,
Engert
F
,
Bader
U
,
Philipp
N
, et al
.
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
.
Leukemia
.
2023
;
37
(
6
):
1298
310
.
55.
Kellmann
SJ
,
Dubel
S
,
Thie
H
.
A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs
.
mAbs
.
2017
;
9
(
3
):
404
18
.
56.
Peng
H
,
Nerreter
T
,
Mestermann
K
,
Wachter
J
,
Chang
J
,
Hudecek
M
, et al
.
ROR1-targeting switchable CAR-T cells for cancer therapy
.
Oncogene
.
2022
;
41
(
34
):
4104
14
.
57.
He
C
,
Mansilla-Soto
J
,
Khanra
N
,
Hamieh
M
,
Bustos
V
,
Paquette
AJ
, et al
.
CD19 CAR antigen engagement mechanisms and affinity tuning
.
Sci Immunol
.
2023
;
8
(
81
):
eadf1426
.
58.
Lock
D
,
Monjezi
R
,
Brandes
C
,
Bates
S
,
Lennartz
S
,
Teppert
K
, et al
.
Automated, scaled, transposon-based production of CAR T cells
.
J Immunother Cancer
.
2022
;
10
(
9
):
e005189
.
59.
van der Schans
JJ
,
Katsarou
A
,
Kladis
G
,
Bar
C
,
Ramirez
MM
,
Themeli
M
, et al
.
A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells
.
J Genet Eng Biotechnol
.
2024
;
22
(
4
):
100446
.